Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector

Truenat is a novel molecular assay that rapidly detects tuberculosis (TB) and rifampicin-resistance. Due to the portability of its battery-powered testing platform, it may be valuable in peripheral healthcare settings in India.

This study, using a mathematical model, projected the clinical impact, costs, and cost-effectiveness of Truenat, as a replacement for smear microscopy or Xpert in India’s public sector.

URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0218890

1 Like